ClinicalTrials.Veeva

Menu

Hybrid Exercise Program for Heart Disease: Effect on Health and Quality of Life

U

University of Malaya

Status

Not yet enrolling

Conditions

Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))

Treatments

Other: Usual Care
Other: Hybrid Endurance Strength Training

Study type

Interventional

Funder types

Other

Identifiers

NCT07130045
2025116-14608
FRGS/1/2023/SS10/UITM/03/4 (Other Grant/Funding Number)

Details and patient eligibility

About

Cardiac rehabilitation (CR) participation remains suboptimal, partly due to logistical challenges and limited access to center-based programs. Hybrid Endurance-Strength Training (HybEST) offers an alternative model by combining supervised endurance and strength exercises with home-based components. The main questions it aims to answer are:

  • Does a hybrid exercise program significantly improve a patient's body function and structures [exercise capacity, body composition, and muscle strength] compared to usual care?
  • Does a hybrid exercise program significantly improve a patient's activity [functional capacity, physical activity, and total energy expenditure] compared to usual care?
  • Does a hybrid exercise program significantly improve a patient's participation [health-related quality of life] compared to usual care?

This single-center, two-arm parallel randomized clinical trial aims to evaluate the effects of HybEST on health-related outcomes and quality of life among patients with coronary artery disease in Phase II CR. Eligible participants will be randomly assigned in a 1:1 ratio to either the HybEST intervention group or the standard CR control group using a lottery method, specifically the sealed envelope approach. Assessments will be conducted at baseline (T0), Week 5 (T2), and Week 9 (T3) to measure changes in health-related outcomes and quality of life.

Full description

In recent years, models for delivering cardiac rehabilitation (CR) have advanced by incorporating structured exercise methods and technology into routine practice. Hybrid Endurance-Strength Training (HybEST) combines supervised center-based sessions with home-based elements, supported by digital tools such as remote monitoring and virtual consultations. This hybrid approach may help overcome common barriers to CR participation, including travel distance, scheduling conflicts, and work commitments. This single-centre, two-arm parallel randomized controlled trial aims to evaluate the effects of a hybrid exercise program in patients with coronary heart disease. The objectives are;

  • To evaluate the effects of a hybrid exercise program on patients' body function and structures, including exercise capacity, body composition, and muscle strength, compared to usual care.
  • To determine the effects of a hybrid exercise program on patients' activity, including functional capacity, physical activity, and total energy expenditure, compared to usual care.
  • To assess the effects of a hybrid exercise program on patients' participation, specifically health-related quality of life, compared to usual care.

A total of 84 eligible participants (42 per group, accounting for 14% attrition) will be randomized into either the intervention or control group. The usual care group will follow a standard exercise program consisting of endurance and strength components. This program includes supervised exercise sessions at the center once a week for eight weeks, along with educational materials on exercising at home. The intervention group will participate in a hybrid training program that combines endurance and strength training over eight weeks. Their program includes two supervised sessions at the center and 22 unsupervised sessions at home. Participants will receive exercise educational videos via WhatsApp (Weeks 1-8) and a fitness tracker to support unsupervised sessions. Weekly virtual follow-ups will be conducted from Week 1 to Week 8. Outcome measures include Exercise Capacity, Body Composition, Muscle Strength, Physical Activity and METs, Barrier Scales, and Health-Related Quality of Life. Data will be analyzed using IBM SPSS version 26.0, with statistical significance set at p < 0.05.

Enrollment

84 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age of 18 years or older.
  • Diagnosed with coronary artery disease (CAD), with or without invasive treatment, maintaining a normal sinus rhythm and preserved left ventricular ejection fraction (LVEF).
  • In a stable clinical condition.
  • capable of regularly attending a supervised exercise program.
  • Able to complete questionnaires in English or Malay.

Exclusion criteria

  • They exhibited abnormal responses during the initial exercise test, such as irregular haemodynamic responses, ST segment depression greater than 2 mm, or any ventricular fibrillation.
  • Their forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) is less than 50% of the predicted value.
  • They cannot participate in exercise testing due to non-cardiac limitations.
  • They have been hospitalized due to heart failure within the past year.
  • They have uncontrollable hypertension.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

84 participants in 2 patient groups

Hybrid Endurance and Strength Training (HybEST)
Experimental group
Description:
HybEST will be delivered three times weekly over eight weeks; there will be two supervised sessions at the center and 22 unsupervised sessions at home.
Treatment:
Other: Hybrid Endurance Strength Training
Usual Care (UC)
Active Comparator group
Description:
The UC group participants will participate in combined endurance and strength training similar to the intervention group's weekly center-based session over eight weeks.
Treatment:
Other: Usual Care

Trial contacts and locations

1

Loading...

Central trial contact

Anwar Suhaimi; Aliff Latir

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems